Acrivon Therapeutics, Inc. Form 8-K Summary
Business context and reporting period
Acrivon Therapeutics, Inc. filed a Form 8-K dated March 3, 2023 under Item 8.01 (Other Events). The filing concerns the company’s first annual meeting of stockholders, expected to be held on June 22, 2023, subject to adjournment or postponement.
Financial metrics and liquidity
The filing does not provide revenue, profit, cash flow, margin, debt, liquidity, or other financial metrics.
Material changes versus the prior comparable period
The filing text does not report financial or operational changes versus a prior period.
Annual meeting deadlines and other matters
- Rule 14a-8 stockholder proposals for inclusion in the proxy materials must be received by the company’s Secretary by March 13, 2023.
- Director nominations and other stockholder proposals outside Rule 14a-8 must be delivered by March 17, 2023, in accordance with the company’s amended and restated bylaws and applicable law.
- The company stated that proxy materials describing the meeting’s business and voting procedures would be distributed before the meeting.
Investor verification items
- Verify the final date, time, format, and agenda of the 2023 annual meeting in the proxy statement.
- Review the proxy materials for voting matters, director nominations, and any subsequent amendments or postponements.
- Confirm compliance with the stated March 13 and March 17 submission deadlines and applicable procedural requirements.